Vecuronium bromide
Norcuron (vecuronium bromide) is a small molecule pharmaceutical. Vecuronium bromide was first approved as Norcuron on 1984-04-30.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vecuronium bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORCURON | Organon | N-018776 DISCN | 1984-04-30 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vecuronium bromide | ANDA | 2023-01-18 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Delayed emergence from anesthesia | D055191 | — | — | — | 1 | 1 | 2 | ||
| Anesthesia | D000758 | — | — | 1 | 1 | — | 2 | ||
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | 1 | — | 1 |
| Rotator cuff injuries | D000070636 | M75.1 | — | — | — | 1 | — | 1 | |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | 1 | — | 1 |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | 1 | — | 1 |
| Neuromuscular blockade | D019148 | — | — | — | 1 | — | 1 | ||
| Confusion | D003221 | F44.89 | — | — | — | 1 | — | 1 | |
| Brain injuries | D001930 | S06.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| General anesthesia | D000768 | — | 1 | 1 | — | 1 | 3 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VECURONIUM BROMIDE |
| INN | vecuronium bromide |
| Description | Vecuronium bromide is the organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents. It has a role as a nicotinic antagonist, a neuromuscular agent and a muscle relaxant. It is a quaternary ammonium salt and an organic bromide salt. It contains a vecuronium. It is functionally related to a 5alpha-androstane. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents; quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1.[Br-] |
Identifiers
| PDB | — |
| CAS-ID | 50700-72-6 |
| RxCUI | 11153 |
| ChEMBL ID | CHEMBL1200629 |
| ChEBI ID | 9940 |
| PubChem CID | 39764 |
| DrugBank | DB01339 |
| UNII ID | 7E4PHP5N1D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,272 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,258 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more